Published in Infect Dis Obstet Gynecol on March 14, 2005
Cultivation-independent analysis of changes in bacterial vaginosis flora following metronidazole treatment. J Clin Microbiol (2007) 2.06
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59
Comparison between Gram stain and culture for the characterization of vaginal microflora: definition of a distinct grade that resembles grade I microflora and revised categorization of grade I microflora. BMC Microbiol (2005) 1.55
Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol (1991) 20.49
Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med (1983) 16.63
HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet (1997) 7.52
Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis (1999) 6.85
Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. J Clin Microbiol (1983) 4.42
Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol (1988) 3.66
Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol (1997) 2.32
Prenatal microbiological risk factors associated with preterm birth. Br J Obstet Gynaecol (1992) 2.30
Microbiological and histopathological findings in acute pelvic inflammatory disease. Br J Obstet Gynaecol (1987) 1.65
Wet smear compared with gram stain diagnosis of bacterial vaginosis in asymptomatic pregnant women. Obstet Gynecol (2000) 1.58
Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol (2001) 1.51
Assessment of office-based care of sexually transmitted diseases and vaginitis and antibiotic decision-making by obstetrician-gynecologists. Infect Dis Obstet Gynecol (1998) 0.95
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Comparative functional genomics of the fission yeasts. Science (2011) 6.00
Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet (2012) 5.81
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med (2004) 4.30
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med (2010) 4.24
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
The clonality of Staphylococcus aureus nasal carriage. J Infect Dis (2005) 2.39
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials (2008) 2.35
Efficacy of the female condom as a barrier to semen during intercourse. Am J Epidemiol (2003) 2.20
Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.15
Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr (2003) 2.11
CENP-A is required for accurate chromosome segregation and sustained kinetochore association of BubR1. Mol Cell Biol (2005) 2.00
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Partner characteristics, intensity of the intercourse, and semen exposure during use of the female condom. Am J Epidemiol (2003) 1.92
Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis (2008) 1.91
The acceptability of the female and male condom: a randomized crossover trial. Perspect Sex Reprod Health (2004) 1.90
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis (2001) 1.79
Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol (2002) 1.76
Maternal mortality among Afghan refugees in Pakistan, 1999-2000. Lancet (2002) 1.74
Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One (2010) 1.73
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis (2002) 1.73
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest (2011) 1.73
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis (2003) 1.71
Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis (2003) 1.70
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS (2010) 1.63
Strains of Staphylococcus aureus obtained from drug-use networks are closely linked. Clin Infect Dis (2002) 1.63
HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med (2013) 1.59
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol (2009) 1.56
Sperm-specific protein kinase A catalytic subunit Calpha2 orchestrates cAMP signaling for male fertility. Proc Natl Acad Sci U S A (2004) 1.54
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read (2007) 1.53
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS (2012) 1.51
Enhanced molecular typing of treponema pallidum: geographical distribution of strain types and association with neurosyphilis. J Infect Dis (2010) 1.51
Comparison of conventional cervical cytology versus visual inspection with acetic acid among human immunodeficiency virus-infected women in Western Kenya. J Low Genit Tract Dis (2012) 1.50
Common roots: a contextual review of HIV epidemics in black men who have sex with men across the African diaspora. Lancet (2012) 1.48
Clinical experience with Staphylococcus lugdunensis bacteremia: a retrospective analysis. Diagn Microbiol Infect Dis (2004) 1.47
Safe conception for HIV-discordant couples: insemination with processed semen from the HIV-infected partner. Am J Obstet Gynecol (2013) 1.45
Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr (2004) 1.45
Seroprevalence of human herpesvirus 8 infection in Northern Thailand. Clin Infect Dis (2004) 1.45
Involving communities in the design of clinical trial protocols: the BAN Study in Lilongwe, Malawi. Contemp Clin Trials (2006) 1.45
Seasonality of tuberculosis in the United States, 1993-2008. Clin Infect Dis (2012) 1.44
Surveillance for Shiga toxin-producing Escherichia coli, Michigan, 2001-2005. Emerg Infect Dis (2007) 1.44
Functional magnetic stimulation facilitates gastric emptying. Arch Phys Med Rehabil (2002) 1.43
Interpreting the association between HIV and bone mineral density. AIDS (2007) 1.43
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis (2007) 1.37
Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology (2009) 1.37
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis (2006) 1.37
Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis (2002) 1.35
Current sexual activity and risky sexual behavior in older men with or at risk for HIV infection. AIDS Educ Prev (2007) 1.33
High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol (2010) 1.31
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer (2006) 1.28
Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis (2003) 1.28
Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. AIDS (2002) 1.27
Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. J Infect Dis (2003) 1.27
Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. J Acquir Immune Defic Syndr (2008) 1.26
Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis (2008) 1.25
Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS (2007) 1.22
Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis (2011) 1.21
Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr (2004) 1.21
Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis (2003) 1.20
Efficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: a randomized clinical trial. Am J Epidemiol (2007) 1.20
Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr (2003) 1.20
Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol (2006) 1.20
Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992-2007. AIDS (2007) 1.19
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev (2005) 1.17
Crack cocaine use and other risk factors for tuberculin positivity in drug users. Clin Infect Dis (2002) 1.14